Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

32 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-01

Study Completion Date

2021-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with extramedullary leukemia were identified over 10 years (January 2003 to September 2019). Clinicopathological,genetic-molecular features were identified and survival outcomes were studied and analyzed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia

NCT01251159

Leukemia

COMPLETED

Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00544999

Leukemia

UNKNOWN PHASE1

Study of Bone Marrow Samples From Patients With Acute Leukemia

NCT00897559

Leukemia

COMPLETED

Biomarkers in Patients With Acute Myeloid Leukemia

NCT01138319

Leukemia

COMPLETED

Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia

NCT01229956

Leukemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We retrospectively collected patients demographics ,including clinicopathological and genetic-molecular parameters in patients with extramedullary leukemia between January 2003 till September 2019 from King Hussein cancer center(KHCC) electronic medical records. All potential prognostic factors were identified and compared with worldwide data published previously. Treatment and survival outcomes were studies and analyzed.

Primary endpoint : Overall survival (OS).

Secondary endpoint :

* Progression Free Survival (PFS).
* incidence of extramedullary leukemia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with extramedullary leukemia(eAML) with myeloid neoplasms

retrospective data analysis

Intervention Type OTHER

chart review, analysis and reporting outcomes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

retrospective data analysis

chart review, analysis and reporting outcomes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subjects aged ≥18 year and up to 75 years
* Male and females.
* Initially diagnosed and treated with extramedullary leukemia at KHCC and followed till last encounter.
* Patients, who underwent an allogeneic stem cell transplant.
* Period January 2003-September 2019